SUSPECT PULMONARY FIBROSIS
—a common threat across a wide range of interstitial lung diseases (ILDs), including connective tissue disease-associated interstitial lung diseases (CTD-ILDs). Pulmonary fibrosis can become a key driver of irreversible harm and early mortality, and calls for urgent identification and intervention.1-4Find out more about the Critical Threat
PROGRESSIVE FIBROSING ILD PHENOTYPE
See what Vincent Cottin, Professor of Respiratory Medicine, has to say about the threat of pulmonary fibrosis across a range of ILDs
THE IMPORTANCE OF HRCT SCANS ON BASELINE
See what Clive Kelly, Senior Lecturer, has to say about the prevalence of pulmonary fibrosis in patients with connective tissue diseases
YOUR VIGILANCE CAN MAKE A DIFFERENCE
Pulmonary fibrosis is an insidious, unpredictable threat.
Understand the pathophysiology of pulmonary fibrosis and hear an
expert's view on the threat across a range of ILDs.
Flaherty KR, Brown KK, Wells AU, et al. Design of the PF-ILD trial: a double-blind, randomised, placebo-controlled phase III trial of ... in patients with progressive fibrosing interstitial lung disease. BMJ Open Resp Res. 2017;4(1):e000212.
Patterson KC, Strek ME. Pulmonary fibrosis in sarcoidosis. Clinical features and outcomes. Ann Am Thorac Soc. 2013;10(4):362-370.
Caban JJ, Yao J, Bagci U, Mollura DJ. Monitoring pulmonary fibrosis by fusing clinical, physiological, and computed tomography features. Conf Proc IEEE Eng Med Biol Soc. 2011;6216-6219.
Wells AU, Brown KK, Flaherty KR, Kolb M, Thannickal VJ, on behalf of the IPF Consensus Working Group. What’s in a name? That which we call IPF, by any other name would act the same. Eur Resp J. 2018;51:1800692.